Roche and Bavarian Nordic have unveiled plans to assess the former’s anti-PD-L1 antibody Tecentriq in combination with the latter’s cancer vaccine candidate CV301 in bladder cancer.
Bristol-Myers Squibb has agreed to supply Bavarian Nordic with Opdivo for use in a clinical trial assessing the immunotherapy in combination with experimental drug CV301.